An Open Label Phase II Study of Aprepitant for Multi-Day Moderately-High to Highly Emetogenic Chemotherapy Regimens

Trial Profile

An Open Label Phase II Study of Aprepitant for Multi-Day Moderately-High to Highly Emetogenic Chemotherapy Regimens

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2013

At a glance

  • Drugs Aprepitant; Dexamethasone; Ondansetron; Prochlorperazine
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Aug 2009 Actual patient number (22) and actual end date (1 Jan 2009) added as reported by ClinicalTrials.gov.
    • 05 Aug 2009 Actual patient number (22) and actual end date (1 Jan 2009) added as reported by ClinicalTrials.gov.
    • 05 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top